Illinois GLP 1 coverage for state workers takes 18 percent of the drug budget

Illinois pays for GLP 1 weight loss drugs in its state employee health plan, and the bill is now big enough to matter in national politics. Governor JB Pritzker told Semafor this week that Illinois GLP 1 coverage reaches about 32,000 state employees and family members at a total cost of $149 million, which his office puts at 18% of the state's prescription budget. Pritzker, who takes a GLP 1 himself, says the state is tracking whether the spending pays off. Medicaid enrollees in Illinois get no weight loss coverage.

What the Illinois state employee health plan pays

The state employee health plan in Illinois covered GLP 1 drugs only for diabetes until 2024, when it added weight loss. Local station WAND reports that adult members qualify with a diagnosis of prediabetes, gestational diabetes or obesity, so Illinois GLP 1 coverage is not open to anyone who simply wants to lose weight. The figures Pritzker's office gave Semafor show how far that choice has grown. About 32,000 members now take the drugs, and the total cost stands at $149 million. Semafor did not say which months that total covers. An earlier Chicago Sun-Times figure, repeated by NPR Illinois, put the cost of the expansion at $147 million in fiscal year 2025, so the two numbers may describe different periods.

The governor's office also offered a comparison. Brand name specialty drugs, used by about 6,500 employees, take 41% of the same prescription budget, more than twice the GLP 1 share. Simple division of the office's own numbers gives a rough sense of scale. GLP 1 spending works out to about $4,700 per user, while the specialty drugs come to roughly $52,000 per user. That math is ours, not the state's, and it rests on totals whose time frame was not given. It still shows the case Pritzker is making. The weight loss benefit costs a lot in total because so many people use it, not because each prescription is the most expensive item the plan pays for.

Why the Pritzker GLP 1 story matters to payers

Pritzker learned he had type 2 diabetes in 2024 and started insulin, Semafor reports, and a doctor added a GLP 1 a few months later. He says he has since lost about 80 pounds and no longer needs insulin. NPR Illinois reported that his own prescription is paid by the state plan because of his diabetes, not as a weight loss claim. That detail matters to members of any plan with a weight loss exclusion, since a diabetes diagnosis can keep the same drug covered. The Pritzker GLP 1 story is also a policy pitch. He told Semafor that if the savings hold up, a candidate could campaign on them, and that falling prices should open the drugs to everyone. He has not pushed private employers to cover them.

About 32,000 members now take the drugs, and the total cost stands at $149 million.

The open question is timing. Semafor notes that the typical American stays in a job for about four years, while federal budget scorers judge health effects over ten years. An employer that pays for the drugs may never see savings if workers leave first. Pritzker argued that state staff tend to stay longer, which could help Illinois recover some of the cost. Yet the savings case is not settled. Our earlier report on studies that found no savings showed big employers dropping weight loss cover for 2027. In a September interview reported by NPR Illinois, Pritzker said he could not rule out future cuts to weight loss coverage, adding that "virtually everything these days is on the table."

Medicaid GLP 1 coverage is moving the other way

Public plans for people on low incomes are moving the other way. Semafor counts seven states that had expanded Medicaid GLP 1 coverage for weight loss and then, this year, either ended the benefit or tightened who qualifies. It did not name the seven. Illinois GLP 1 coverage for weight loss never reached Medicaid, and Pritzker said in September that doing so is not feasible now, given other demands on Medicaid dollars and pressure from Washington. Semafor adds that Medicaid cuts in a 2025 federal tax law, due to start next year, are expected to squeeze state budgets further. For an enrollee, that means access to these drugs for weight loss may depend more on the state they live in than on their diagnosis.

The stakes are large because the pool of possible patients is large. A 2024 KFF study, as described by Semafor, found that more than 40% of privately insured Americans under 65 could be clinically eligible for GLP 1 drugs, depending on the criteria used. About 32 million Americans already take them, Semafor reports. Employers face the same math as states. A WTW survey we covered found the share of larger employers covering weight loss fell to 53% from 57%, as costs for 2027 climb. Medicare is a separate track. Its temporary Bridge program, which this site has reported on, charges eligible patients a flat monthly copay and is set to end on December 31, 2027.

GLP 1 out of pocket costs and the 2028 race

People outside these plans pay at the counter, and GLP 1 out of pocket costs remain high. Semafor described $1,528 a year as the average spend for people on a GLP 1. The study behind that figure, published in the Journal of General Internal Medicine, defines it differently. It is the median yearly out of pocket amount per user in federal survey data from 2013 to 2023, and it was highest among privately insured and higher income adults. The same paper found that nearly one in five users spent 10% or more of household income on these drugs, a burden heaviest for uninsured, publicly insured and low income adults. For cash payers today, Semafor reports that Novo Nordisk advertises Wegovy and Ozempic at $149 to $399 a month, depending on dose.

The 2028 presidential race, which begins in earnest after next week's midterms, will be the first in which these drugs are a routine household cost. The ideas offered so far come mostly from outside government. Philanthropist John Arnold urged Congress to close loopholes that he says Novo Nordisk and Eli Lilly could use to delay generic GLP 1 competition, while warning that mandated coverage would be expensive. Zachariah Reitano, chief executive of the telehealth company Ro, suggested the government use its scale to negotiate prices and pay for patients who stay on treatment. A National Review writer argued that government should stay out entirely. Federal pressure has already produced a White House pricing deal with both makers.

Conclusion

Illinois GLP 1 coverage shows both sides of the access question inside one state. About 32,000 people get the drugs through the state employee plan, while Medicaid enrollees in the same state have no weight loss cover. The total is large, the savings are unproven, and the governor has not ruled out cuts. Watch whether Illinois publishes the savings data it says it is tracking, and whether 2028 candidates name a price and a payer in their GLP 1 plans. This report is for information only and is not medical advice.